Article Abstract

Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?

Authors: Arpit Rao, Emmanuel S. Antonarakis


Metastatic castration-resistant prostate cancer (mCRPC) is a condition characterized by cancer progression in the setting of low serum testosterone levels (1,2), and represents the lethal phase of the disease. Biologically, the development of castration-resistance occurs through a multitude of primarily androgen receptor (AR)-dependent mechanisms such as AR amplification, AR mutation, AR splice variant expression, and increase in synthesis of intratumoral and adrenal androgens through CYP17 and other pathways (3,4).

Article Options

Download Citation